Oncodesign

Foundation date

05/01/1995

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oncodesign is a biopharma company dedicated to the precision medicine. Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB.

Upcoming events

Latest news

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

  • Mithra announces Estelle® launch in Belgium

    Thursday October 21st 2021

  • Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes

    Wednesday October 20th 2021